SPA
SAGE

Sherbrooke Park Advisers’s Sage Therapeutics SAGE Stock Holding History

Sherbrooke Park Advisers’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,058
Closed -$188K – 1168
2024
Q1 		$188K Buy
+10,058
New +$232K 0.04% 736

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sherbrooke Park Advisers's SAGE Position: Q2 2024 in Review

Sherbrooke Park Advisers sold out of Sage Therapeutics (SAGE) in Q2 2024, closing a stake of 10,058 shares — an estimated $188K sold.

Sherbrooke Park Advisers first reported a position in SAGE in Q1 2024 and held it in 1 quarter. The position peaked at $188K in Q1 2024. 193 funds tracked by Wall St. Rank hold SAGE as of Q2 2024.

  • Sherbrooke Park Advisers reported no remaining Sage Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 10,058 Sage Therapeutics shares in Q2 2024, an estimated $188K.
  • Sherbrooke Park Advisers first reported a position in Sage Therapeutics in Q1 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Sage Therapeutics position peaked at $188K in Q1 2024.
  • 193 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.